Isotype : IgG3, k chain

Literature references :
Ellis IO, Robins RA, Elston CW, Blamey RW, Ferry B, Baldwin RW A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization.  Histipathology  1984 8(3):501-16

Robertson JF, Pearson D, Price MR, Selby C, Badley RA, Pearson J, Blamey RW, Howell A.  Assessment of four monoclonal antibodies as serum markers in breast cancer.  Eur J Cancer 1990 26(11-12):1127-32

Price MR, Pugh JA, Hudecz F, Griffiths W, Jacobs E, Symonds IM, Clarke AJ, Chan WC, Baldwin RW. C595--a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas.  Br J Cancer 1990 61(5):681-6

Price MR, Hudecz F, O'Sullivan C, Baldwin RW, Edwards PM, Tendler SJ  Immunological and structural features of the protein core of human polymorphic epithelial mucin.  Mol Immunol 1990 27(8):795-802

Origin, source : BALB/c Mice were immunised with the defined epithelial antigen isolated from normal urine of NCR-11 antibody (IgM) which was raised against human breast carcinoma. The hybridomas were screened for high reactivity against the immunising antigen using a radioisotopic antiglobulin assay, then they were teste on immunihistology on breast cancer carcinoma tissues.

Specificity : The C595 antibody specifically reacts with the tetrameric epitope RPAP within the tandem repeat domain of MUC1.

Cross-reactivity : The LICRL/M8 antibody and the C595 antibody have closely related epitopes.

Binding Assays : In sandwich assays performed using C595 and NCRC-11 antibodies, the epithelial mucin isolated from breast carcinoma,  ovarian mucinous and serous carcinoma, normal urine and human skim milk were recognised by the C595 antibody in sandwich assay with itself and with NCRC-11 antibody.

Immunoblotting : The C595 antibody was positive with epithelial mucin preparations isolated from normal urine and breast by affinity chromatography with NCRC-11 antibody.

Solid phase radioisotopic antiglobulin assay:
The reactivity of the C595 antibody was positive with extra nuclear membrane from breast tumor and from normal tissues. There was a high reactivity with  the tumor sample and no reactivity with the sample from normal tissues. The C595 antibody was not reacting with extra nuclear membrane from normal or tumor  colorectal tissues.

Immunohistochemistry Results from Price et al publication:
Experiments on cryostat section fixed in acetone.
 

Positive Tissues	Negative tissues
Breast carcinoma Breast (Acini and ducts) Kidney (distal tubules and collecting tubules) Bladder Lung (+/-)	Brain (cerebral cortex) Stomach Kidney (Promixal tubules) Small intestine Liver (Parenchyma) Spleen / Lymph nodes Testis Muscles (Striated, smooth and cardia)

Other publications using the 595 antibody: To find many more publications see "Pub Med"
                      I
Hughes OD, Perkins AC, Frier M, Wastie ML, Denton G, Price MR, Denley H, Bishop MC  maging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595.  BJU Int 2001 Jan;87(1):39-46

 Hughes OD, Bishop MC, Perkins AC, Wastie ML, Denton G, Price MR, Frier M, Denley H, Rutherford R, Schubiger PA.  Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595.  J Clin Oncol. 2000 Jan;18(2):363-70.

Croce MV, Colussi AG, Price MR, Segal-Eiras A.  Identification and characterization of different subpopulations in a human lung adenocarcinoma cell line (A549).  Pathol Oncol Res. 1999;5(3):197-204.

Simms MS, Hughes OD, Limb M, Price MR, Bishop MC.  MUC1 mucin as a tumour marker in bladder cancer.  BJU Int. 1999 Aug;84(3):350-2.

 Denton G, Brady K, Lo BK, Murray A, Graves CR, Hughes OD, Tendler SJ, Laughton CA, Price MR.  Production and characterization of an anti-(MUC1 mucin) recombinant diabody.  Cancer Immunol Immunother. 1999 Apr;48(1):29-38.

Spencer DI, Missailidis S, Denton G, Murray A, Brady K, Matteis CI, Searle MS, Tendler SJ, Price MR.  Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.  Biospectroscopy. 1999;5(2):79-91.

 Murray A, Spencer DI, Missailidis S, Denton G, Price MR. Design of ligands for the purification of anti-MUC1 antibodies by peptide epitope affinity chromatography.  J Pept Res. 1998 Nov;52(5):375-83.

Croce MV, Colussi AG, De Bravo MG, Price MR, Segal-Eiras A. Immunohistopathological characterizatin of spontaneous metastases in a human lung mucoepidermoid adenocarcinoma (HLMC) xenograft.  Pathol Oncol Res. 1998;4(4):259-66.

Schol DJ, Meulenbroek MF, Snijdewint FG, von Mensdorff-Pouilly S, Verstraeten RA, Murakami F, Kenemans P, Hilgers J.  'Epitope fingerprinting' using overlapping 20-mer peptides of the MUC1 tandem repeat sequence.  Tumour Biol. 1998;19 Suppl 1:35-45.

Denton G, Sekowski M, Spencer DI, Hughes OD, Murray A, Denley H, Tendler SJ, Price MR.  Production and characterization of a recombinant anti-MUC1 scFv reactive with human carcinomas.  Br J Cancer. 1997;76(5):614-21.

Hughes OD, Bishop MC, Perkins AC, Frier M, Price MR, Denton G, Smith A, Rutherford R, Schubiger PA.  Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer.  Eur J Nucl Med. 1997 Apr;24(4):439-43.

Spencer DI, Price MR, Tendler SJ, De Matteis CI, Stadie T, Hanisch FG.  Effect of glycosylation of a synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies.  Cancer Lett. 1996 Feb 27;100(1-2):11-5.

Price MR, Clarke AJ, Robertson JF, O'Sullivan C, Baldwin RW, Blamey RW.    Detection of polymorphic epithelial mucins in the serum of systemic breast cancer patients using the monoclonal antibody, NCRC-11.  Cancer Immunol Immunother 1990;31(5):269-72

Notes : Made by CRC Laboratory.  Nottingham